期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

可溶性人基质裂解素2在肺部炎症性疾病的作用研究进展 被引量：7

Advance of soluble suppression of tumorigenicity 2 in inflammatory lung diseases
原文传递
导出
摘要 可溶性人基质裂解素2 （soluble Suppression of tumorigenicity 2,sST2）是人基质裂解素2 （ST2）亚型之一,其可作为IL-33的受体,选择性表达于Th2细胞,在免疫反应和炎症疾病中发挥重要作用.近年研究发现IL-33与sST2结合,在肺部炎症性疾病中发挥重要作用,如社区获得性肺炎、慢性支气管炎、COPD、哮喘和ARDS.本文对sST2在肺部炎症性疾病中的作用研究进展作一综述. sST2 is one of the isoforms of ST2,which is known to be a ligand for IL-33 and is selectively expressed on Th2 cells and plays an important role in the immune response and inflammatory diseases.In recent surveys,sST2 is in combination withIL-33,which plays an important role in inflammatory lung diseases,such as community-acquired pneumonia,chronic bronchitis,chronic obstructive pulmonary disease,asthma and acute respiratory distress syndrome.This review focuses on the research advances in inflammatory lung diseases.
作者 朱默然 许德凤 刘锦铭
机构地区 浦东新区公立医院呼吸科 同济大学附属肺科医院肺循环科
出处 《国际呼吸杂志》 2016年第10期779-781,共3页 International Journal of Respiration
关键词 可溶性人基质裂解素2 白细胞介素33 肺炎 sST2 Interleukin 33 Pneumonia
分类号 R563.1 [医药卫生—呼吸系统]
  • 相关文献

参考文献1

二级参考文献22

  • 1Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970-1062.
  • 2Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
  • 3Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
  • 4Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial Infarction. Circulation 2008; 117: 1936-1944.
  • 5Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011; 61:1163-1170.
  • 6Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardio12010; 55: 243-250.
  • 7Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010; 159: 788- 794.
  • 8Granger CB, Goldberg R J, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2006;163: 2345-2353.
  • 9Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479- 490.
  • 10Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 innon-st-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58: 257-266.

共引文献27

同被引文献82

引证文献7

二级引证文献23

国际呼吸杂志
2016年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部